Print
News
Sequenom licenses worldwide rights to develop age-related macular degeneration diagnostic test
Download the PDF
February 9, 2010
Optherion completes $37 million start up financing
Download the PDF
October 9, 2007
Optherion
New Haven, CT
Optherion is an early-stage biotechnology company that is developing therapeutics and diagnostic tools for age-related macular degeneration (AMD) and orphan renal diseases strongly influenced by components of the alternative complement system. Optherion's technologies are based on recent genetic discoveries linking certain genes to these disorders.